Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CYCLOSPHOSPHAMIDE THERAPY OF MEDULLOBLASTOMA - FROM THE LABORATORY TOTHE CLINIC AND BACK AGAIN (AND AGAIN AND AGAIN)
Autore:
FRIEDMAN HS; BIGNER SH; BIGNER DD;
Indirizzi:
DUKE UNIV,MED CTR,DEPT PEDIAT,BOX 2916 DURHAM NC 27710 DUKE UNIV,MED CTR,DEPT PATHOL DURHAM NC 27710 DUKE UNIV,MED CTR,PREUSS LAB BRAIN TUMOR RES DURHAM NC 27710
Titolo Testata:
Journal of neuro-oncology
fascicolo: 1, volume: 24, anno: 1995,
pagine: 103 - 108
SICI:
0167-594X(1995)24:1<103:CTOM-F>2.0.ZU;2-#
Fonte:
ISI
Lingua:
ENG
Soggetto:
EXPERIMENTAL CHEMOTHERAPY; CELL-LINES; C-MYC; CYCLOPHOSPHAMIDE; AMPLIFICATION; XENOGRAFTS; CHILDREN; TUMORS; MODEL;
Keywords:
CYCLOPHOSPHAMIDE; MEDULLOBLASTOMA; ALKYLATING AGENTS; BRAIN TUMOR;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
21
Recensione:
Indirizzi per estratti:
Citazione:
H.S. Friedman et al., "CYCLOSPHOSPHAMIDE THERAPY OF MEDULLOBLASTOMA - FROM THE LABORATORY TOTHE CLINIC AND BACK AGAIN (AND AGAIN AND AGAIN)", Journal of neuro-oncology, 24(1), 1995, pp. 103-108

Abstract

Medulloblastoma, the most common malignancy of childhood, was originally shown to be sensitive to cyclophosphamide in 1981. We have used combined laboratory and clinical investigations to demonstrate the synergy of cyclophosphamide and vincristine in the treatment of this tumor,the therapeutic gain associated with escalation of the dosage of cyclophosphamide, the consequence of and mechanisms underlying resistance of medulloblastoma to cyclophosphamide, the emerging importance of theneuroaxis as a site of relapse of medulloblastoma, and newer approaches, including intrathecal 4-hydroperoxycyclophosphamide and busulfan, to treat neuraxis disease. These studies serve as a paradigm for laboratory-clinical translational research.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/09/20 alle ore 13:48:30